GLPBio

survivin (baculoviral IAP repeat-containing protein 5) (21-28)

Catalog No.: GP10034Purity:>98%Synonyms: H2N-Thr-Phe-Lys-Asn-Trp-Pro-Phe-Leu-OH

Cancer Biology Peptides

Les produits sont exclusivement destinés à la recherche. Ils ne doivent pas être utilisés chez l’être humain. Nous ne vendons pas aux patients.


survivin (baculoviral IAP repeat-containing protein 5) (21-28)
1mgIn Stock
$37.00
1
5mgIn Stock
$107.00
1
10mgIn Stock
$178.00
1
25mgIn Stock
$253.00
1

Citations

Aucune citation n’est actuellement disponible pour ce produit. Vous trouverez ci-dessous une sélection de publications citant des produits GlpBio.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

Survivin (baculoviral inhibitor of apoptosis IAP repeat-containing protein-5) is a member of the IAP gene family, which has been implicated in both inhibition of apoptosis and mitosis regulation1. Survivin is one of the most uniformly up-regulated genes in tumor tissues compared with healthy tissues2. High survivin expression in the primary tumor is almost invariably associated with poor patient prognosis in many cancer types. Survivin relates to poor disease outcome in a variety of tumors, i.e., neuroblastoma3, colorectal cancer4, non-small-cell lung cancers5, B-cell lymphoma6, T-cell leukemia7, hepatocellular carcinoma, esophageal carcinoma, rectal cancer, glioma, bladder cancer, soft tissue sarcoma and astrocytic tumors.

Survivin mRNA, as measured by quantitative RT-PCR in the primary tumor, has strong and independent prognostic value in human breast cancer. Survivin mRNA concentrations in the tumor can be used to classify breast cancer patients into different risk groups. 8 Cells that are unresponsive to apoptotic triggers will also be more resistant to cytotoxic treatments, as are cells that overexpress survivin9.

References:
1.Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46 -54.
2.Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nat Genet 1999; 23:387-8.
3.Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998; 351:882-3.
4.Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58:5071-4.
5.Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17:2100 -4.
6.Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96:1921-5.
7.Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk Lymphoma 2002; 43:2249 -55.
8.Paul N. Span, Fred C.G.J. Sweep et al. Survivin Is an Independent Prognostic Marker for Risk Stratification of Breast Cancer Patients. Clinical Chemistry 50:11; 1986 -1993 (2004)
9.Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002; 5:65-72.

Documents produit (Product Documents)

Propriétés chimiques (Chemical Properties)

Synonymes
H2N-Thr-Phe-Lys-Asn-Trp-Pro-Phe-Leu-OH
SMILES
NC(C(C)O)C(NC(CC1=CC=CC=C1)C(NC(CCCCN)C(NC(CC(N)=O)C(NC(CC2=CNC3=C2C=CC=C3)C(N4C(C(NC(CC5=CC=CC=C5)C(NC(CC(C)C)C(O)=O)=O)=O)CCC4)=O)=O)=O)=O)=O
Formule moléculaire
C54H73N11O11
Masse moléculaire
1052.22
Solubilité
≥105.2mg/mL in DMSO
Conservation
Store at -20°C
Conseils généraux
Choisissez un solvant adapté selon les données de solubilité du produit. Après préparation, répartissez la solution mère en aliquotes afin d’éviter les cycles répétés de congélation-décongélation.
Utilisez les solutions mères dans les 6 mois si elles sont conservées à -80°C, ou dans le mois si elles sont conservées à -20°C.
Pour améliorer la solubilité, réchauffez le tube à 37°C et soniquez-le pendant une durée appropriée.
Conditions d’expédition
Les échantillons d’évaluation sont expédiés avec des blocs réfrigérants. Les autres formats sont expédiés à température ambiante ou, sur demande, avec des blocs réfrigérants.

Calculateurs (Calculators)Molarité / Dilution / Masse moléculaire / Conversion d’unités / Formulation in vivo / Solubilité

g/mol

Reviews

Review for survivin (baculoviral IAP repeat-containing protein 5) (21-28)

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%